Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Melanoma

Free Subscription 31.08.2026 2 Am J Ophthalmol 2 Ann Surg Oncol 1 Br J Dermatol 1 Eur J Dermatol 3 J Am Acad Dermatol 1 J Clin Invest 1 J Invest Dermatol 4 Melanoma Res 1 PLoS Comput Biol 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Ophthalmol

1. ARSLAN GD, Alizada M, Ciftci S, Beser BG, et al
   Repeat Gene Expression Profiling, PRAME Status, and Next-Generation Sequencing Testing in Uveal Melanoma Undergoing Secondary Therapy.
   Am J Ophthalmol. 2026 Aug 25:S0002-9394(26)00485.
   PubMed         Abstract available
   
   
2. BOURKE L, Horgan N, Murtagh P
   Occult ciliary body melanoma masquerading as refractory glaucoma.
   Am J Ophthalmol. 2026 Aug 24:S0002-9394(26)00477.
   PubMed        
   
   

   
   Ann Surg Oncol

3. DAVIS L, Van Doren AS
   ASO Author Reflections: Real-World Insights into Melanoma Biopsy Selection and Staging Accuracy.
   Ann Surg Oncol. 2026 Aug 27. doi: 10.1245/s10434-026-20478.
   PubMed        
   
   
4. MCCAHILL LE, Grosh K, Schmitt C, Hunt A, et al
   ASO Visual Abstract: Missed Opportunities for Neoadjuvant Immunotherapy in Melanoma-Is it Time to Consider Ultrasound Staging for Newly Diagnosed Patients?
   Ann Surg Oncol. 2026 Aug 25. doi: 10.1245/s10434-026-20462.
   PubMed        
   
   

   
   Br J Dermatol

5. ZHANG J, Wang H, Zheng Q, Liu M, et al
   High-dimensional overfitting and noisy diagnostic labels: reconsidering the role of BRAF copy number in primary dermal melanoma.
   Br J Dermatol. 2026 Aug 24:ljag348. doi: 10.1093.
   PubMed        
   
   

   
   Eur J Dermatol

6. MATSUZAKI Y, Maeda T, Uehara J, Shibahara T, et al
   Successful retreatment with dabrafenib and trametinib for cardiac metastases of BRAF-mutated melanoma after adjuvant therapy.
   Eur J Dermatol. 2026;36:0.
   PubMed        
   
   

   
   J Am Acad Dermatol

7. BADAT S, Houmsse MM, Fakult NJ, Mani K, et al
   Trends in Cutaneous Melanoma in the United States Using SEER.
   J Am Acad Dermatol. 2026 Aug 24:S0190-9622(26)03392.
   PubMed        
   
   
8. REYNOLDS CE, Fay AB, Rundle CW, Tripathi R, et al
   Geospatial associations between county-level elevation, socioeconomic status, healthcare access, and SEER melanoma incidence.
   J Am Acad Dermatol. 2026 Aug 26:S0190-9622(26)03407.
   PubMed        
   
   
9. HUHMANN LB, Hwang JC, Perez D, Kim DY, et al
   A retrospective cohort study using the Veterans Affairs Cancer Registry database: Increased hazard of Parkinson's disease in United States Veterans with melanoma.
   J Am Acad Dermatol. 2026 Aug 27:S0190-9622(26)03400.
   PubMed        
   
   

   
   J Clin Invest

10. DHODAPKAR KM, Matera A, Duffy AM, Taz A, et al
    B-cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma.
    J Clin Invest. 2026 Aug 25:e205606. doi: 10.1172/JCI205606.
    PubMed         Abstract available
    
    

    
    J Invest Dermatol

11. AOYAMA K, Kawashima S, Saeki Y, Kawahara Y, et al
    Blockade for CD276-mediated suppression of tumor-specific cytotoxic T lymphocytes may contribute to achieving durable responses with immune checkpoint inhibitors.
    J Invest Dermatol. 2026;146:2554-2564.
    PubMed         Abstract available
    
    

    
    Melanoma Res

12. BOUDZOUMOU E, Croix M, L'Orphelin JM
    NF1 alterations as potential biomarker in acral melanoma: looking beyond low tumor mutational burden.
    Melanoma Res. 2026;36:476-478.
    PubMed        
    
    
13. TARHINI AA, Khaksar MA, Chen Z, Lee SJ, et al
    Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2026;36:407-415.
    PubMed         Abstract available
    
    
14. IVANOVA M, Stojkovski I, Klisarovska V
    Treatment discontinuation after complete response to BRAF/MEK inhibition in metastatic melanoma: long-term clinical outcomes from a single institution.
    Melanoma Res. 2026 Aug 24. doi: 10.1097/CMR.0000000000001134.
    PubMed         Abstract available
    
    
15. TOMMASINO N, Guerriero L, Palagiano C, Costa C, et al
    Melanoma simulators: a retrospective study of nonmelanocytic mimickers.
    Melanoma Res. 2026 Aug 24. doi: 10.1097/CMR.0000000000001137.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

16. CAMACHO LQ, Fallahi-Sichani M
    Systematic multivariate analysis of chromatin complex dependencies reveals Set1C/COMPASS as a melanoma-enriched epigenetic vulnerability.
    PLoS Comput Biol. 2026;22:e1014018.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

17. CHEN YC, Bollu VS, Kheirabadi S, LaPenna K, et al
    Convergent roles of GDF-15 in mechanotransduction, vascular disorganization, and immune suppression in melanoma.
    Proc Natl Acad Sci U S A. 2026;123:e2602594123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum